Breaking News

Immuno-Oncology Candidate in Combination with Checkpoint Treatment Looks Promising for Melanoma Treatment

February 2, 2022 • 8:33 am CST
(Vax Before Cancer)

California-based Mosaic ImmunoEngineering, Inc. today announced a new article published in the journal Molecular Pharmaceuticals that details broad immune activation of inactivated CPMV (termed inCPMV) and potent, systemic, and durable antitumor activity with the treatment combination in an aggressive two-tumor model of melanoma.

Co-authors of the new article, "Inactivated Cowpea Mosaic Virus in Combination with OX40 Agonist Primes Potent Antitumor Immunity in a Bilateral Melanoma Mouse Model," include Mosaic co-founders Nicole F. Steinmetz, Ph.D., director of the UC San Diego Center for Nano-ImmunoEngineering, and Steven N. Fiering, Ph.D., professor of microbiology and immunology at the Geisel School of Medicine at Dartmouth University.

The article highlights include the following:

  • Broad, durable, and systemic antitumor immunity observed using inCPMV with OX40 agonist antibodies,
  • Intratumoral inCPMV administration in combination with systemic anti-OX40 controlled the progression of the primary as well as untreated secondary tumors, and
  • 70% of animals survived for at least 100 days post tumor challenge without the development of recurrence or metastatic disease.

"Our studies demonstrate that intratumoral administration of inCPMV and systemic administration of an OX40 agonist antibody generates potenantitumorc antitumor immunity," said Dr. Steinmetz in a press release issued on February 2, 2022.

"We observed that synergistic efficacy can be achieved through a combination of inCPMV with an OX40 agonist."

"These data further support the rationale for combining our lead immuno-oncology product candidate, MIE-101, with antibodies targeting OX40, which are currently showing promise in clinical development for the treatment of cancer."

"The potential of MIE-101 to turn immunologically cold tumors hot could allow checkpoint treatment approaches such as OX40 agonists to be effective in more patients who do not currently respond," added Steven King, president, and CEO of Mosaic.

"Checkpoint targeted treatments have shown promising and durable results in melanoma patients, yet there remains a significant unmet medical need because only a minority of patients receive the full potential clinical benefit to currently approved therapies. These results published by Mosaic's co-founders reinforce our goal to continue identifying strategic partners to work with us as we advance MIE-101."

Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company located in Novato, CA, focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. 

Share